Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Department of Dermatology, Takamatsu Red Cross Hospital, Takamatsu, Japan.
J Dermatol. 2022 Feb;49(2):246-252. doi: 10.1111/1346-8138.16057. Epub 2021 Jul 14.
To identify clonal neoplastic cells in skin affected by B-cell lymphoma using skin flow cytometry (FCM) techniques, we investigated light-chain restriction using skin FCM with clonality assessed by polymerase chain reaction and light-chain restriction by in situ hybridization (ISH). We retrospectively analyzed 16 cases of B-cell lymphoma with cutaneous involvement: primary cutaneous diffuse large B-cell lymphoma, leg type (pcDLBCL-LT) (n = 7), DLBCL-not otherwise specified (DLBCL-NOS) (n = 6), primary cutaneous follicle center lymphoma (pcFCL) (n = 1), and follicular lymphoma (n = 2), as well as cutaneous B-cell pseudolymphoma (n = 9). Results of skin FCM light-chain restriction analyses were compared with immunoglobulin H (IgH) gene rearrangement and κ/λ ISH findings. Skin FCM detected light-chain restriction in 11 of 14 B-cell lymphoma patients but none of the B-cell pseudolymphoma patients. The sensitivity of skin FCM for distinguishing B-cell lymphoma and B-cell pseudolymphoma was 79%, and the specificity was 100%. Eleven of 13 B-cell lymphoma patients exhibited gene rearrangement (sensitivity 85%), whereas six of seven pseudolymphoma patients were negative (specificity 86%). ISH was positive in three of 16 B-cell lymphoma cases (sensitivity 19%) but none of the B-cell pseudolymphoma cases (specificity 100%). ISH sensitivity was 29% for pcDLBCL-LT, 17% for DLBCL-NOS, and 0% for pcFCL and follicular lymphoma. Skin FCM therefore appears to be more sensitive than ISH in detecting light-chain restriction in DLBCL and follicular lymphoma, and as sensitive as IgH gene rearrangement analysis in detecting clonality. Skin FCM is thus a promising diagnostic tool for identifying monoclonal neoplastic B-cell populations.
为了使用皮肤流式细胞术 (FCM) 技术在受 B 细胞淋巴瘤影响的皮肤中识别克隆性肿瘤细胞,我们使用皮肤 FCM 研究了轻链限制,并通过聚合酶链反应评估了克隆性,通过原位杂交 (ISH) 评估了轻链限制。我们回顾性分析了 16 例皮肤受累的 B 细胞淋巴瘤病例:原发性皮肤弥漫性大 B 细胞淋巴瘤,腿型 (pcDLBCL-LT) (n=7)、非特指性弥漫性大 B 细胞淋巴瘤 (DLBCL-NOS) (n=6)、原发性皮肤滤泡中心淋巴瘤 (pcFCL) (n=1) 和滤泡性淋巴瘤 (n=2) ,以及皮肤 B 细胞假性淋巴瘤 (n=9)。皮肤 FCM 轻链限制分析的结果与免疫球蛋白 H (IgH) 基因重排和 κ/λ ISH 结果进行了比较。皮肤 FCM 在 14 例 B 细胞淋巴瘤患者中的 11 例中检测到轻链限制,但在 9 例 B 细胞假性淋巴瘤患者中均未检测到。皮肤 FCM 区分 B 细胞淋巴瘤和 B 细胞假性淋巴瘤的敏感性为 79%,特异性为 100%。13 例 B 细胞淋巴瘤患者中有 11 例存在基因重排 (敏感性 85%),而 7 例假性淋巴瘤患者中有 6 例为阴性 (特异性 86%)。ISH 在 16 例 B 细胞淋巴瘤病例中的 3 例中呈阳性 (敏感性 19%),但在 9 例 B 细胞假性淋巴瘤病例中均为阴性 (特异性 100%)。ISH 的敏感性分别为 pcDLBCL-LT 的 29%、DLBCL-NOS 的 17%、pcFCL 和滤泡性淋巴瘤的 0%。因此,皮肤 FCM 在检测 DLBCL 和滤泡性淋巴瘤中的轻链限制方面似乎比 ISH 更敏感,在检测克隆性方面与 IgH 基因重排分析一样敏感。因此,皮肤 FCM 是一种很有前途的诊断工具,可以识别单克隆肿瘤 B 细胞群体。